This presentation will cover how to use Practice Fusion to participate in PQRS using the EHR Reporting Method. Additionally, Practice Fusion supports 27 CQMs, 14 of which were recently released. Each of the new CQMs that Practice Fusion supports will be reviewed in detail.
Measuring & Monitoring Clinical Quality Measures Using Practice FusionPractice Fusion
Review CMS quality measures, how to capture the data in Practice Fusion, and how this data can be used to earn incentive payments through quality reporting programs, including Meaningful Use and PQRS.
Clinical Quality Measures: Measuring and monitoring clinical quality measures...Practice Fusion
Learn about:
1. CMS quality measures.
2. How to capture the data in Practice Fusion.
3. How this data can be used to earn incentive payments through quality reporting programs, including Meaningful Use and PQRS.
Measuring and Monitoring Clinical Quality Measures in Practice FusionKimberly Hilton
Clinical Quality Measures (CQMs) are used to measure and monitor the quality of care provided in practices. CQMs consist of numerators and denominators that are defined by measure specifications. Practice Fusion supports recording CQM data elements to report on over 25 CQMs across all six National Quality Strategy domains. Providers can record screening results, assessments, and follow-up plans in the patient chart to submit CQM data for quality reporting programs.
New clinical quality measure reporting in Practice Fusion [slides]Practice Fusion
Learn about the new data elements, which quality measures they can be used for, and information on reporting quality measures using Practice Fusion for Meaningful Use, PQRS EHR Reporting, and other quality improvement programs.
This document discusses the requirements for Meaningful Use Stage 2. It outlines the core and menu objectives including clinical quality measures, electronic prescribing, health information exchange, patient electronic access, and secure messaging. It provides guidance on exclusions and gives workflows within Practice Fusion for how to meet each objective. Key requirements include reporting 9 clinical quality measures covering 3 domains, using computerized physician order entry for 60% of medications and incorporating structured lab results.
Measuring & Monitoring Clinical Quality Measures Using Practice FusionPractice Fusion
Review CMS quality measures, how to capture the data in Practice Fusion, and how this data can be used to earn incentive payments through quality reporting programs, including Meaningful Use and PQRS.
Clinical Quality Measures: Measuring and monitoring clinical quality measures...Practice Fusion
Learn about:
1. CMS quality measures.
2. How to capture the data in Practice Fusion.
3. How this data can be used to earn incentive payments through quality reporting programs, including Meaningful Use and PQRS.
Measuring and Monitoring Clinical Quality Measures in Practice FusionKimberly Hilton
Clinical Quality Measures (CQMs) are used to measure and monitor the quality of care provided in practices. CQMs consist of numerators and denominators that are defined by measure specifications. Practice Fusion supports recording CQM data elements to report on over 25 CQMs across all six National Quality Strategy domains. Providers can record screening results, assessments, and follow-up plans in the patient chart to submit CQM data for quality reporting programs.
New clinical quality measure reporting in Practice Fusion [slides]Practice Fusion
Learn about the new data elements, which quality measures they can be used for, and information on reporting quality measures using Practice Fusion for Meaningful Use, PQRS EHR Reporting, and other quality improvement programs.
This document discusses the requirements for Meaningful Use Stage 2. It outlines the core and menu objectives including clinical quality measures, electronic prescribing, health information exchange, patient electronic access, and secure messaging. It provides guidance on exclusions and gives workflows within Practice Fusion for how to meet each objective. Key requirements include reporting 9 clinical quality measures covering 3 domains, using computerized physician order entry for 60% of medications and incorporating structured lab results.
The document discusses key aspects of Meaningful Use Stage 1, including:
1) Eligible providers can qualify for EHR incentive payments through Medicare or Medicaid by meeting Meaningful Use objectives such as recording patient demographics and smoking status for a specified number of patients.
2) There are three stages of Meaningful Use with increasing requirements to improve outcomes, such as engaging patients and improving care coordination.
3) Providers have until February 28th of the following year to attest they met Meaningful Use requirements for an incentive payment for the prior year. Failure to meet requirements could result in penalties under Medicare.
Clinical Quality Measures (CQMs) for Meaningful Use & PQRSEmily Richmond
This presentation provides information on reporting clinical quality measures (CQMs) for Meaningful Use and PQRS, while also providing detailed information on the quality measure specifications that Practice Fusion currently supports.
Practice Fusion is a free, web-based, 2014 certified complete ambulatory EHR.
www.practicefusion.com/signup/
Meaningful Use Stage 2 and Health Information Exchange (HIE)MassEHealth
Transformational intent of Meaningful Use (MU) and the increased trend toward interoperability in MU Stage 2 (MU2); MU2 objectives with an HIE component and their MU2 measures; Approaches to achieving the transitions of care; Available public health registries and their current status and submission pathway; How to find a trading partner and best practices to engaging
This document provides an overview of electronic clinical quality measures (eCQMs) and the transition from manual chart abstraction to electronic reporting of quality measures. It discusses upcoming requirements for eCQM reporting to CMS programs like IQR and the vision for a unified set of electronically specified measures. The document reviews the eCQM reporting process including planning, testing, validation and submission. Challenges and opportunities of eCQM reporting are also addressed.
The Alabama Regional Extension Center helps healthcare providers in Alabama select, implement, and meaningfully use certified electronic health record (EHR) technology. Its mission is to improve healthcare quality and value through education, outreach, and technical assistance regarding EHR adoption. The Center is part of the University of South Alabama College of Medicine and provides guidance to help providers achieve meaningful use objectives and avoid Medicare payment adjustments.
This document discusses electronic clinical quality measures (eCQMs) and the transition to mandatory eCQM reporting. It notes that the 2016 IPPS rule will require hospitals to submit 4 eCQMs beginning in 2016. Additional programs like Joint Commission and Outpatient Quality Reporting are also moving to require eCQMs. The document reviews the eCQM reporting process and considerations for eCQM selection. It provides an example of eCQM reporting for the VTE-3 measure and submission in the QRDA format. Looking ahead, value-based programs and the transition to consolidated quality programs through MACRA are discussed.
The document provides guidance on the 2007 Physician Quality Reporting Initiative (PQRI) for eligible medical professionals. It describes the goals of the PQRI to focus on quality of care and reward reporting of quality measures with financial incentives. It outlines the eligible professionals, quality measures, reporting requirements, and bonus payments for successful reporting. It also provides details on understanding the quality measures, applicable codes, modifiers, and examples of successful reporting.
How to Engage Physicians in Quality/Safety Improvement Using MetricsWellbe
The unsustainable rising cost of medical care is creating financial pressures that will critically alter the way that health care is both paid for and delivered. Limited resources dictate that we become more efficient at providing high quality care. In an effort to provide financial incentive for delivering quality care the Federal government instituted Value Based Purchasing (VBP) and Bundled Payments. In order to maximize reimbursement under these programs, providers of health care must follow to the basic tenants of the quality principles.
Lorraine Hutzler, Associate Director of the Center for Quality and Patient Safety at NYU Hospital for Joint Diseases at the NYU Langone Medical Center, will discuss:
• How to build a quality infrastructure for your orthopedic program
• What quality metrics to measure and how to engage surgeons using them
• Lean and Six Sigma principles to use to accelerate improvement
About the Speaker:
Lorraine100Lorraine Hutzler is the Associate Director of the Center for Quality and Patient Safety at NYU Hospital for Joint Diseases at the NYU Langone Medical Center and a Principal of Labrador Healthcare Consulting. She designed, built and maintains a robust quality infrastructure for the Department of Orthopaedic Surgery. Lorraine has extensive expertise in quality metrics management and reporting as well as Lean and Six Sigma Certification.
This document provides an overview and summary of quality in healthcare initiatives. It discusses the industry background and shift towards quality and value-based care. It outlines key federal quality programs like CMS Star Ratings and accrediting entities like NCQA. It also summarizes Puerto Rico's quality retention fund and examples of clinical quality measures like breast cancer screening and diabetes management. Finally, it reviews risk adjustment programs in Medicare Advantage, Commercial ACA, and Managed Medicaid.
This document discusses various methods for quantifying medicine needs, including the patient morbidity-standard treatment method and the adjusted consumption method. It compares the advantages and disadvantages of each. Critical issues in quantification are also outlined, such as preparing an action plan, estimating quantities while considering factors like lead time and losses. The ideal inventory model and calculations for safety stock, consumption, and budgeting are demonstrated. Effective medicines supply management requires selection, quantification, procurement, distribution, and use.
Our Insights webinar this week tackles a little-known program that will have a big impact on fee-for-service Medicare providers. The Value-Based Payment Modifier (or Value Modifier for short) is something every Medicare provider should know about as soon as possible. One way or another, providers will wind up on either the incentive or penalty side of this legislation. Take advantage of our webinar for in-depth information on this complex and far-reaching topic.
- The document discusses the requirements and incentives for physicians to achieve Meaningful Use of electronic health records as part of the government's stimulus program.
- Physicians must meet objectives in three stages involving electronic prescribing, clinical quality reporting, and advanced clinical processes to receive incentive payments of up to $44,000 from Medicare or $63,750 from Medi-Cal.
- Achieving Meaningful Use requires efforts from physicians, medical assistants, and office staff according to defined roles and responsibilities for data capture, review, and reporting.
Presentation: Spotlight on prescription medicines reformsTGA Australia
An overview of initiatives arising from the Review of Medicines and Medical Devices Regulation relevant to prescription medicines as well as orphan drugs and developments for eCTD and the new MedSearch app.
TGA presentation: MMDR Consultation - Strengthening monitoring of medicines i...TGA Australia
The document outlines new and enhanced pharmacovigilance activities being implemented by the TGA to strengthen post-market monitoring of medicines in Australia. Key changes include establishing a Pharmacovigilance Inspections Program, implementing a Black Triangle Scheme, monitoring compliance with Risk Management Plans, developing a new Adverse Events Management System, reformatting Product Information, and increasing collaboration with overseas regulators and use of advanced data analytics. The changes aim to ensure the ongoing safety of medicines on the Australian market through improved monitoring and risk mitigation strategies.
TGA presentation: Provisional approval pathway for prescription medicinesTGA Australia
This presentation provided an overview of some of the reform activities relevant to prescription, OTC and complementary medicines and implementation of recommendations from the Review of Medicines and Medical Devices Regulation including the content of the consultations on enhancements
MACRA will help us move more quickly towards our goal of value-based care. MIPS combines parts of the Physician Quality Reporting System (PQRS), the Value Modifier (VM or Value-based Payment Modifier), and the Medicare Electronic Health Record (EHR) incentive program into one single program. Have a look at the objectives & measures, quality scoring methodology, clinical practice improvements and other pertinent details.
The document discusses proposed expedited pathways for prescription medicines in Australia, including a Priority Review pathway. It outlines proposed eligibility criteria focusing on serious conditions with unmet needs where the medicine provides a major therapeutic advantage.
A draft designation process is presented involving assessment of eligibility criteria within 6-8 weeks. Designations would lapse if no registration submission is made within 3 months. Appeals of designation decisions are proposed.
Priority Review is aimed to complete assessments in 150 working days through flexible business processes and expert advice. Provisional Approval could grant earlier conditional registration based on early safety and efficacy data, with enhanced post-market monitoring required. Public consultation on
EHR certification requirements, and the capabilities an EHR should build to be eligible for QPP. Interoperability, data access and security are some of the core of QPP.
Meaningful Use encompasses multiple stages, each with specific timeline and measure requirements that continue to be a moving target. This can be a confusing process, sending providers in a tailspin in their attempts to stay current. This webinar focuses on the overall details of Meaningful Use and provides a nice outline of all of its details.
Using Practice Fusion for PQRS EHR Reporting in 2014Practice Fusion
This presentation is an overview of PQRS requirements in 2014, requirements for PQRS EHR reporting, and measure selection and EHR reporting applicability. The presentation will also give a deep dive into using Practice Fusion for PQRS reporting.
The document discusses clinical quality measures (CQMs) and reporting CQMs through Practice Fusion to meet requirements for programs like Meaningful Use and PQRS. It explains that providers are increasingly evaluated on quality and outcomes, describes key quality programs and their CQM reporting requirements, and provides guidance on selecting applicable CQMs and the reporting process through Practice Fusion.
The document discusses key aspects of Meaningful Use Stage 1, including:
1) Eligible providers can qualify for EHR incentive payments through Medicare or Medicaid by meeting Meaningful Use objectives such as recording patient demographics and smoking status for a specified number of patients.
2) There are three stages of Meaningful Use with increasing requirements to improve outcomes, such as engaging patients and improving care coordination.
3) Providers have until February 28th of the following year to attest they met Meaningful Use requirements for an incentive payment for the prior year. Failure to meet requirements could result in penalties under Medicare.
Clinical Quality Measures (CQMs) for Meaningful Use & PQRSEmily Richmond
This presentation provides information on reporting clinical quality measures (CQMs) for Meaningful Use and PQRS, while also providing detailed information on the quality measure specifications that Practice Fusion currently supports.
Practice Fusion is a free, web-based, 2014 certified complete ambulatory EHR.
www.practicefusion.com/signup/
Meaningful Use Stage 2 and Health Information Exchange (HIE)MassEHealth
Transformational intent of Meaningful Use (MU) and the increased trend toward interoperability in MU Stage 2 (MU2); MU2 objectives with an HIE component and their MU2 measures; Approaches to achieving the transitions of care; Available public health registries and their current status and submission pathway; How to find a trading partner and best practices to engaging
This document provides an overview of electronic clinical quality measures (eCQMs) and the transition from manual chart abstraction to electronic reporting of quality measures. It discusses upcoming requirements for eCQM reporting to CMS programs like IQR and the vision for a unified set of electronically specified measures. The document reviews the eCQM reporting process including planning, testing, validation and submission. Challenges and opportunities of eCQM reporting are also addressed.
The Alabama Regional Extension Center helps healthcare providers in Alabama select, implement, and meaningfully use certified electronic health record (EHR) technology. Its mission is to improve healthcare quality and value through education, outreach, and technical assistance regarding EHR adoption. The Center is part of the University of South Alabama College of Medicine and provides guidance to help providers achieve meaningful use objectives and avoid Medicare payment adjustments.
This document discusses electronic clinical quality measures (eCQMs) and the transition to mandatory eCQM reporting. It notes that the 2016 IPPS rule will require hospitals to submit 4 eCQMs beginning in 2016. Additional programs like Joint Commission and Outpatient Quality Reporting are also moving to require eCQMs. The document reviews the eCQM reporting process and considerations for eCQM selection. It provides an example of eCQM reporting for the VTE-3 measure and submission in the QRDA format. Looking ahead, value-based programs and the transition to consolidated quality programs through MACRA are discussed.
The document provides guidance on the 2007 Physician Quality Reporting Initiative (PQRI) for eligible medical professionals. It describes the goals of the PQRI to focus on quality of care and reward reporting of quality measures with financial incentives. It outlines the eligible professionals, quality measures, reporting requirements, and bonus payments for successful reporting. It also provides details on understanding the quality measures, applicable codes, modifiers, and examples of successful reporting.
How to Engage Physicians in Quality/Safety Improvement Using MetricsWellbe
The unsustainable rising cost of medical care is creating financial pressures that will critically alter the way that health care is both paid for and delivered. Limited resources dictate that we become more efficient at providing high quality care. In an effort to provide financial incentive for delivering quality care the Federal government instituted Value Based Purchasing (VBP) and Bundled Payments. In order to maximize reimbursement under these programs, providers of health care must follow to the basic tenants of the quality principles.
Lorraine Hutzler, Associate Director of the Center for Quality and Patient Safety at NYU Hospital for Joint Diseases at the NYU Langone Medical Center, will discuss:
• How to build a quality infrastructure for your orthopedic program
• What quality metrics to measure and how to engage surgeons using them
• Lean and Six Sigma principles to use to accelerate improvement
About the Speaker:
Lorraine100Lorraine Hutzler is the Associate Director of the Center for Quality and Patient Safety at NYU Hospital for Joint Diseases at the NYU Langone Medical Center and a Principal of Labrador Healthcare Consulting. She designed, built and maintains a robust quality infrastructure for the Department of Orthopaedic Surgery. Lorraine has extensive expertise in quality metrics management and reporting as well as Lean and Six Sigma Certification.
This document provides an overview and summary of quality in healthcare initiatives. It discusses the industry background and shift towards quality and value-based care. It outlines key federal quality programs like CMS Star Ratings and accrediting entities like NCQA. It also summarizes Puerto Rico's quality retention fund and examples of clinical quality measures like breast cancer screening and diabetes management. Finally, it reviews risk adjustment programs in Medicare Advantage, Commercial ACA, and Managed Medicaid.
This document discusses various methods for quantifying medicine needs, including the patient morbidity-standard treatment method and the adjusted consumption method. It compares the advantages and disadvantages of each. Critical issues in quantification are also outlined, such as preparing an action plan, estimating quantities while considering factors like lead time and losses. The ideal inventory model and calculations for safety stock, consumption, and budgeting are demonstrated. Effective medicines supply management requires selection, quantification, procurement, distribution, and use.
Our Insights webinar this week tackles a little-known program that will have a big impact on fee-for-service Medicare providers. The Value-Based Payment Modifier (or Value Modifier for short) is something every Medicare provider should know about as soon as possible. One way or another, providers will wind up on either the incentive or penalty side of this legislation. Take advantage of our webinar for in-depth information on this complex and far-reaching topic.
- The document discusses the requirements and incentives for physicians to achieve Meaningful Use of electronic health records as part of the government's stimulus program.
- Physicians must meet objectives in three stages involving electronic prescribing, clinical quality reporting, and advanced clinical processes to receive incentive payments of up to $44,000 from Medicare or $63,750 from Medi-Cal.
- Achieving Meaningful Use requires efforts from physicians, medical assistants, and office staff according to defined roles and responsibilities for data capture, review, and reporting.
Presentation: Spotlight on prescription medicines reformsTGA Australia
An overview of initiatives arising from the Review of Medicines and Medical Devices Regulation relevant to prescription medicines as well as orphan drugs and developments for eCTD and the new MedSearch app.
TGA presentation: MMDR Consultation - Strengthening monitoring of medicines i...TGA Australia
The document outlines new and enhanced pharmacovigilance activities being implemented by the TGA to strengthen post-market monitoring of medicines in Australia. Key changes include establishing a Pharmacovigilance Inspections Program, implementing a Black Triangle Scheme, monitoring compliance with Risk Management Plans, developing a new Adverse Events Management System, reformatting Product Information, and increasing collaboration with overseas regulators and use of advanced data analytics. The changes aim to ensure the ongoing safety of medicines on the Australian market through improved monitoring and risk mitigation strategies.
TGA presentation: Provisional approval pathway for prescription medicinesTGA Australia
This presentation provided an overview of some of the reform activities relevant to prescription, OTC and complementary medicines and implementation of recommendations from the Review of Medicines and Medical Devices Regulation including the content of the consultations on enhancements
MACRA will help us move more quickly towards our goal of value-based care. MIPS combines parts of the Physician Quality Reporting System (PQRS), the Value Modifier (VM or Value-based Payment Modifier), and the Medicare Electronic Health Record (EHR) incentive program into one single program. Have a look at the objectives & measures, quality scoring methodology, clinical practice improvements and other pertinent details.
The document discusses proposed expedited pathways for prescription medicines in Australia, including a Priority Review pathway. It outlines proposed eligibility criteria focusing on serious conditions with unmet needs where the medicine provides a major therapeutic advantage.
A draft designation process is presented involving assessment of eligibility criteria within 6-8 weeks. Designations would lapse if no registration submission is made within 3 months. Appeals of designation decisions are proposed.
Priority Review is aimed to complete assessments in 150 working days through flexible business processes and expert advice. Provisional Approval could grant earlier conditional registration based on early safety and efficacy data, with enhanced post-market monitoring required. Public consultation on
EHR certification requirements, and the capabilities an EHR should build to be eligible for QPP. Interoperability, data access and security are some of the core of QPP.
Meaningful Use encompasses multiple stages, each with specific timeline and measure requirements that continue to be a moving target. This can be a confusing process, sending providers in a tailspin in their attempts to stay current. This webinar focuses on the overall details of Meaningful Use and provides a nice outline of all of its details.
Using Practice Fusion for PQRS EHR Reporting in 2014Practice Fusion
This presentation is an overview of PQRS requirements in 2014, requirements for PQRS EHR reporting, and measure selection and EHR reporting applicability. The presentation will also give a deep dive into using Practice Fusion for PQRS reporting.
The document discusses clinical quality measures (CQMs) and reporting CQMs through Practice Fusion to meet requirements for programs like Meaningful Use and PQRS. It explains that providers are increasingly evaluated on quality and outcomes, describes key quality programs and their CQM reporting requirements, and provides guidance on selecting applicable CQMs and the reporting process through Practice Fusion.
The Design of Accountable Care OrganizationsCJ Fulton
Pillars for Accountable Care
PCMH versus ACOs
Core competencies
Six core structural components of successful ACO deployment
Pioneer ACO burn and learn lessons
Barriers & root cause analysis
Patient attribution
Five modes of Accountable Care
Early value-based adopters
Value discovery assessment
Modified Triple Aim
GPRO
Breakdown by 33 Measures
Keynote Presentation "Meaningful Use Stage 2 and Meaningful Use Audit Insight"
Think far beyond just threshold increases. The differences between Meaningful Use (MU) Stage 1 and Stage 2, including the 2014 Clinical Quality Measures, are technically and clinically challenging. And just when you thought you could safely look at Stage 1 in the rearview mirror, here come the audits! I will highlight the Stage 1 and Stage 2 differences and talk about the challenges they have initiated at Tenet. I will touch on the impact of Quality measures and will also provide you with insight into the basics of MU Audits and will take you through the actual audit experience at Tenet.
Learning Objectives:
∙ Review the program and measure changes from Stage 1 to Stage 2 and how the changes are being managed at Tenet
∙ Provide insight into the 2014 Clinical Quality Measures chosen by Tenet, the challenges posed, solutions that work and a little about the overall
impact of Quality measures
∙ Discuss Meaningful Use Audits, covering the basics as well as providing the benefit of the Tenet experience
This document summarizes the American College of Physicians' review and recommendations for several performance measures related to the diagnosis and treatment of rheumatoid arthritis. The ACP supports measures assessing disease-modifying antirheumatic drug therapy, tuberculosis screening before biologic therapy, assessment of disease activity, and functional status assessment. The ACP recommends modifications to measures assessing DMARD therapy and disease prognosis assessment. The ACP does not support measures assessing glucocorticoid management.
PMC Measure Review Diabetes v8FINAL WebsiteSarah West
1. The document reviews several performance measures related to the management of diabetes.
2. It summarizes the American College of Physicians' assessments of three specific measures - supporting one measure conditionally, not supporting another, and supporting a third with modifications.
3. The measures relate to eye exams, foot exams, and hemoglobin A1c control in patients with diabetes.
This document discusses pharmaceutical care, which aims to improve patient outcomes through responsible drug therapy. It defines pharmaceutical care as providing medication to achieve definite therapeutic outcomes that improve quality of life. These outcomes include curing disease, reducing symptoms, slowing disease progression, and preventing disease. The document outlines the basic elements of pharmaceutical care, which are patient-oriented and focus on both acute and chronic issues, prevention of drug problems, and optimizing health quality of life. It also discusses various tools used in pharmaceutical care, including SOAP notes, CORE pharmacotherapy plans, and FARM notes.
Clinical Audits and Process Improvement in HospitalsLallu Joseph
How to conduct a clinical audit, differences between research and clinical audit, medical audit, History of audit, benefits of audit, standard, criteria, benchmarks, compare performance, examples of clinical audit, audit cycle, types of audit, NABH, JCI, QAPI, PDCA, Hospital accreditation,
This document provides an overview and summary of changes between the proposed rule and final rule for implementing the Medicare and Medicaid EHR Incentive Program under the HITECH Act. Some key changes included modifications to the meaningful use criteria and clinical quality measures, clarification of provider eligibility requirements, and adjustment of measure thresholds. The final rule aimed to address concerns raised in public comments to better achieve the goals of improved care, health outcomes, and interoperability.
Protocols and Pathways Ischemic and Hemorrhagic Strokes.pptFitz Jaminit
This document discusses protocols and clinical pathways for ischemic and hemorrhagic stroke. It defines clinical pathways as multidisciplinary and evidence-based approaches to standardized patient care, while protocols provide guideline-based outlines for managing specific conditions. The document reviews evidence that clinical pathways can streamline stroke care, avoid delays, and improve outcomes. It identifies key components for inclusion in ischemic and hemorrhagic stroke pathways, such as diagnostic testing, treatment guidelines, and monitoring plans. Examples of pathways are provided to illustrate components like blood pressure and nutrition management in the first 72 hours after different stroke types.
This document summarizes changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program's meaningful use criteria. Key changes included lowering thresholds for some objectives, removing administrative transactions, adding new objectives, and modifying clinical quality measures for eligible professionals. The final rule provided more flexibility for states and clarified various eligibility and reporting requirements.
HIT Standards Committee Trudel CMS RulesBrian Ahier
The document discusses changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program. Key changes included clarifying provider eligibility, modifying clinical quality measures, and lowering thresholds for some meaningful use objectives. The final rule kept the same statutory requirements and meaningful use goals as the proposed rule.
This document summarizes changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program's meaningful use criteria. Key changes included lowering thresholds for some objectives, removing administrative transactions, adding new objectives, and modifying clinical quality measures requirements for eligible professionals. The final rule provided more flexibility for states and clarified various eligibility and reporting policies to fully implement the program in 2011.
This document summarizes changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program's meaningful use criteria. Key changes included lowering thresholds for some objectives, removing administrative transactions, adding new objectives, and modifying clinical quality measures for eligible professionals. The final rule provided more flexibility for states and clarified various eligibility and reporting requirements.
This document summarizes changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program's meaningful use criteria. Key changes included lowering thresholds for some objectives, removing administrative transactions, adding new objectives, and modifying clinical quality measures for eligible professionals. The final rule provided more flexibility for states and clarified various eligibility and reporting requirements.
This document summarizes changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program's meaningful use criteria. Key changes included lowering thresholds for some objectives, removing administrative transactions, adding new objectives, and modifying clinical quality measures for eligible professionals. The final rule provided more flexibility for states and clarified various eligibility and reporting requirements.
This document summarizes changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program's meaningful use criteria. Key changes included lowering thresholds for some objectives, removing administrative transactions, adding new objectives, and modifying clinical quality measures requirements for eligible professionals. The final rule provided more flexibility for states and clarified various eligibility and reporting policies.
This document summarizes changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program's meaningful use criteria. Key changes included lowering thresholds for some objectives, removing administrative transactions, adding new objectives, and modifying clinical quality measures for eligible professionals. The final rule provided more flexibility for states and clarified various eligibility and reporting requirements.
Similar to New Clinical Quality Measures and PQRS EHR Reporting (20)
This document provides information about 2015 meaningful use and PQRS reporting requirements. It reviews the attestation process for meaningful use and the different reporting options for PQRS. It also demonstrates how to generate and submit a PQRS file using the Practice Fusion dashboard. Homework assignments are given to review meaningful use resources and set up IACS accounts for PQRS reporting.
An electronic health record (EHR) is a digital version of a patient's paper medical chart. An EHR contains the patient's medical history, diagnoses, medications, allergies, immunizations, lab tests, exams, photos, and more. EHRs allow authorized healthcare providers to securely access a patient's information electronically. This improves care coordination and makes health information instantly available across different healthcare organizations. EHR adoption among US doctors has increased in recent years due to federal incentives that aim to improve patient care through "Meaningful Use" of certified EHR systems.
High blood pressure in the U.S. - City by City Trends 2014Practice Fusion
Practice Fusion analyzed a subset of its 81 million de-identified and aggregated patient health records to understand the percentage of patients with hypertension and the percentage of hypertension patients at goal in 17 major U.S. cities. Practice Fusion also compared those numbers to nationwide blood pressure information from the platform.
Meaningful Use Stage 2 Summary of Care Data Exchange with Practice FusionPractice Fusion
Stage 2 of Meaningful Use requires that providers complete three Summary of Care measures related to sending referrals. Practice Fusion has enabled providers to complete these measures through our new referral workflows.
To learn about how these referral workflows work (including Direct messaging) and how these workflows relate to Meaningful Use, review the slideshow. This detailed guide will walk you through understanding Direct and how to enable it, the variety of ways to send a referral in Practice Fusion, and how to achieve the related Meaningful Use measures.
Physician Quality Reporting System (PQRS) is a CMS reporting program that uses a combination of incentive payments and penalties to promote reporting of quality data. This presentation discusses.
This document provides guidance on attesting for Meaningful Use incentives. It outlines the attestation process, including reporting core and menu measures, clinical quality measures, and documentation requirements. Key deadlines are attending by March 20, 2015 for Medicare and before February 28, 2015 for Medicaid. The document reviews completing attestation on the CMS or state Medicaid website and the steps involved in confirming Meaningful Use achievement.
Learn how to enroll your patients in Practice Fusion's patient portal while meeting all your Meaningful Use Stage 1 and Stage 2 requirements. Our recommended workflow maximizes patient engagement while limiting the burden on your staff.
Understanding the Physician Quality Reporting System (PQRS) Requirements in 2014Practice Fusion
This webinar, Understanding the Physician Quality Reporting System (PQRS) Requirements in 2014, goes over which reporting options are available, what the incentives and penalties are for participating, reporting requirements, and how to choose quality measure for reporting.
The document discusses diagnosis counts. It likely contains data on the number of diagnoses made or recorded. The counts may be broken down by category, location, time period, or other factors important for medical reporting and analysis. In summary, the document title "Diagnosis count" indicates it contains numerical data related to medical diagnoses.
COPD Treatment in Ghatkopar,Mumbai. Dr Kumar DoshiDr Kumar Doshi
Are you or a loved one affected by Chronic Obstructive Pulmonary Disease (COPD)? Discover comprehensive and advanced treatment options with Dr. Kumar Doshi, a preeminent COPD specialist based in Ghatkopar, Mumbai.
Dr. Kumar Doshi is dedicated to delivering the highest standard of care for COPD patients. Whether you are seeking a diagnosis, a second opinion, or exploring new treatment avenues, this presentation will guide you through the exceptional services available at his practice in Ghatkopar, Mumbai.
We are one of the top Massage Spa Ajman Our highly skilled, experienced, and certified massage therapists from different corners of the world are committed to serving you with a soothing and relaxing experience. Luxuriate yourself at our spas in Sharjah and Ajman, which are indeed enriched with an ambiance of relaxation and tranquility. We could confidently claim that we are one of the most affordable Spa Ajman and Sharjah as well, where you can book the massage session of your choice for just 99 AED at any time as we are open 24 hours a day, 7 days a week.
Visit : https://massagespaajman.com/
Call : 052 987 1315
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDr Rachana Gujar
Introduction: Substance use education is crucial due to its prevalence and societal impact.
Alcohol Use: Immediate and long-term risks include impaired judgment, health issues, and social consequences.
Tobacco Use: Immediate effects include increased heart rate, while long-term risks encompass cancer and heart disease.
Drug Use: Risks vary depending on the drug type, including health and psychological implications.
Prevention Strategies: Education, healthy coping mechanisms, community support, and policies are vital in preventing substance use.
Harm Reduction Strategies: Safe use practices, medication-assisted treatment, and naloxone availability aim to reduce harm.
Seeking Help for Addiction: Recognizing signs, available treatments, support systems, and resources are essential for recovery.
Personal Stories: Real stories of recovery emphasize hope and resilience.
Interactive Q&A: Engage the audience and encourage discussion.
Conclusion: Recap key points and emphasize the importance of awareness, prevention, and seeking help.
Resources: Provide contact information and links for further support.
Unlocking the Secrets to Safe Patient Handling.pdfLift Ability
Furthermore, the time constraints and workload in healthcare settings can make it challenging for caregivers to prioritise safe patient handling Australia practices, leading to shortcuts and increased risks.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...rightmanforbloodline
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
About this webinar: This talk will introduce what cancer rehabilitation is, where it fits into the cancer trajectory, and who can benefit from it. In addition, the current landscape of cancer rehabilitation in Canada will be discussed and the need for advocacy to increase access to this essential component of cancer care.
Joker Wigs has been a one-stop-shop for hair products for over 26 years. We provide high-quality hair wigs, hair extensions, hair toppers, hair patch, and more for both men and women.
Gemma Wean- Nutritional solution for Artemiasmuskaan0008
GEMMA Wean is a high end larval co-feeding and weaning diet aimed at Artemia optimisation and is fortified with a high level of proteins and phospholipids. GEMMA Wean provides the early weaned juveniles with dedicated fish nutrition and is an ideal follow on from GEMMA Micro or Artemia.
GEMMA Wean has an optimised nutritional balance and physical quality so that it flows more freely and spreads readily on the water surface. The balance of phospholipid classes to- gether with the production technology based on a low temperature extrusion process improve the physical aspect of the pellets while still retaining the high phospholipid content.
GEMMA Wean is available in 0.1mm, 0.2mm and 0.3mm. There is also a 0.5mm micro-pellet, GEMMA Wean Diamond, which covers the early nursery stage from post-weaning to pre-growing.
MBC Support Group for Black Women – Insights in Genetic Testing.pdfbkling
Christina Spears, breast cancer genetic counselor at the Ohio State University Comprehensive Cancer Center, joined us for the MBC Support Group for Black Women to discuss the importance of genetic testing in communities of color and answer pressing questions.
At Apollo Hospital, Lucknow, U.P., we provide specialized care for children experiencing dehydration and other symptoms. We also offer NICU & PICU Ambulance Facility Services. Consult our expert today for the best pediatric emergency care.
For More Details:
Map: https://cutt.ly/BwCeflYo
Name: Apollo Hospital
Address: Singar Nagar, LDA Colony, Lucknow, Uttar Pradesh 226012
Phone: 08429021957
Opening Hours: 24X7
This particular slides consist of- what is Pneumothorax,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is a summary of Pneumothorax:
Pneumothorax, also known as a collapsed lung, is a condition that occurs when air leaks into the space between the lung and chest wall. This air buildup puts pressure on the lung, preventing it from expanding fully when you breathe. A pneumothorax can cause a complete or partial collapse of the lung.
As Mumbai's premier kidney transplant and donation center, L H Hiranandani Hospital Powai is not just a medical facility; it's a beacon of hope where cutting-edge science meets compassionate care, transforming lives and redefining the standards of kidney health in India.
New Clinical Quality Measures and PQRS EHR Reporting
1. New Clinical Quality Measures
and PQRS EHR Reporting
Presented By:
Sophie Scheidlinger
Quality Programs Advisor
2. PQRS
+ PQRS is a CMS quality improvement program that uses
incentives and penalties to promote reporting of quality data
+ Eligibility
Providers who see Medicare Part B patients and are reimbursed
under the Medicare Physician Fee Schedule (PFS)
Physicians, chiropractors, dentists, PAs, NPs, and others
+ 2014 Incentives and Penalties
+0.5% incentive or -2% penalty in 2016
2
3. Reporting Options
+ Note that qualifying
for the incentive
means automatically
avoiding the penalty
+ EHR reporting
method cannot be
used to simply avoid
penalty
3
4. PQRS EHR Reporting
+Criteria for satisfactory EHR reporting
Report on at least 9 measures covering 3 National Quality
Strategy (NQS) domains for all eligible patients during
reporting period
If EHR doesn’t contain patient data for at least 9
measures, then report measures that have Medicare
patient data
Providers must report on at least 1 CQM that has
Medicare patient data
4
5. PQRS EHR Reporting and Practice Fusion
+Practice Fusion will act as a Direct EHR Vendor
(EHR Direct).
This will allow our providers to use Practice Fusion to
directly submit their PQRS measures data to CMS in the
CMS specified format on their own behalf.
Late in 2014, the 2014 CQM Dashboard will allow for
selection of CQMs for reporting and generation of a file
for attestation
Submit a years worth of CQM data to CMS in 2015
5
6. PQRS Measure Selection Considerations
+ When choosing (clinical quality) measures for reporting:
Those of interest and applicable to the practice
Those available under the selected PQRS reporting option
Those that apply to your Medicare patients
+ If CQMs that Practice Fusion supports do not meet these
criteria, providers will need to select another option besides
EHR reporting
6
7. Practice Fusion now supports 27 CQMs
Allowing more Practice Fusion providers to choose
the EHR Reporting Mechanism for PQRS reporting
7
8. Review of 14 newly released Clinical
Quality Measures
8
9. CQM Terminology
• The population of patients or encounters for which
the measure applies. Denominator
• The population of patients from the denominator who meet
the measure specified clinical requirements or the population
of encounters from the denominator where the measure
specific requirement has been performed.
Numerator
• Specifications that would remove a patient from the denominator of a
specific quality measure.
• Includes certain diagnoses that make it clinically unnecessary for the
patient to receive the numerator clinical action and/or provider or
patient determined reasons for refusing certain clinical actions.
Exclusion/Exceptio
n
• This is also known as the EHR reporting period and
refers to the time frame for which the CQMs will be
calculated.
Measurement
period
10. CQM Terminology
• The six NQS domains, one of which is assigned to each CMS
eCQM, are: Patient and Family Engagement, Patient Safety,
Care Coordination, Population and Public Health, Efficient Use
of Healthcare Resources, and Clinical Processes/Effectiveness
National Quality
Strategy (NQS)
Domains
• NQF reviews, endorses, and recommends use of standardized
quality measures. Not all quality measures are “NQF-endorsed,”
but those that are have an assigned NQF number.
National Quality
Forum (NQF)
• Lists of specific values (terms and their codes) derived from
single or multiple standard vocabularies used to define clinical
concepts (e.g. patients with diabetes, clinical visit, reportable
diseases) used in clinical quality measures and to support
effective health information exchange.
Value sets
• An HL7-based standard document format for
reporting clinical quality measure data to CMS for
quality improvement programs.
Quality Reporting
Document Architecture
(QRDA)
11. CMS22v2: Screening for High Blood Pressure and Follow-Up Documented
NQS Domain Population/Public Health
Denominator Numerator
Patients aged 18 and older before
the start of the measurement period.
Patients who were screened for high blood pressure AND have a recommended follow-up
plan documented, as indicated, if the blood pressure is pre-hypertensive or
hypertensive.
Practice Fusion
Suggested
Workflow
After recording the patient’s BP in the chart, determine if the patient is pre-hypertensive or
hypertensive, and then record the following in the Screenings/Interventions/Assessments section of the
new chart:
• Follow-up time frame (4 weeks, 1 year, etc.)
• The selected intervention as “Ordered, Reason (Finding of hypertension)”
Recommended Blood Pressure Follow-Up Interventions
Normal BP: No follow-up required for Systolic BP < 120 mmHg AND Diastolic BP <80 mmHg
Pre-Hypertensive BP: Follow-up with re-screen every year with systolic BP of 120-139 mmHg OR
diastolic BP of 80-89 mmHg AND recommend lifestyle modifications OR referral to Alternative/Primary
Care Provider
First Hypertensive BP Reading: Patients with 1 reading of systolic BP >= 140 mmHg OR diastolic BP
>= 90 mmHg: Follow-up with re-screen > 1 day and < 4 weeks AND recommend lifestyle modifications
OR referral to Alternative/Primary Care Provider
Second Hypertensive BP Reading: Patients with 2nd elevated reading of systolic BP >=140 mmHg OR
diastolic BP >= 90 mmHg: Follow-up with Recommended lifestyle recommendations AND one or more
of the Second Hypertensive Reading Interventions OR referral to Alternative/Primary Care Provider
12. CMS22v2: Screening for High Blood Pressure and Follow-Up Documented
12
Hypertension Screening Ranges
Normal BP Pre-hypertensive BP Hypertensive BP
120/80 mmHg 120/80 mmHg - 139/89 mmHg 140/90 mmHg
• Interventions that meet the numerator criteria of this measure include:
• Hypertension education
• Exercise education or exercise counseling
• Target weight discussed
• Dietary management education, guidance and counseling
• Nutrition education
• Referral to a primary care provider can be used as an intervention for this measure, but
this must be recorded in the Screenings/Intervention/Assessments section of the chart
note since “Finding of Hypertension” cannot be selected in the PF referral workflow.
• Patients who have BP values that are hypertensive (>= 140/90) at two or more visits also
must have one of following recorded:
• Rx for anti-hypertensive pharmacologic therapy,
• A lab order or result for hypertension (CBC with ordered manual differential panel,
urinalysis complete panel, etc.), or
• EKG study or EKG 12 channel panel (recorded under the S/I/A section of the chart)
13. CMS164v2: Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
NQS Domain Clinical Processes/Effectiveness
Denominator Numerator
Patients 18 years of age and older with a visit
during the measurement period, and an
active diagnosis of ischemic vascular disease
(IVD) during the measurement period.
Patients who have documentation of use of
aspirin or another antithrombotic during the
measurement period.
Practice
Fusion
Suggested
Workflow
Medications that meet the numerator criteria for this measure include the
following:
• Prasurgrel (5mg and 10mg oral tablet)
• Aspirin (varying dosages and tablet types, for example: 81 mg chewable
tablet, 80 mg oral tablet, 228 mg chewing gum, 300 mg oral capsule, 162
mg enteric coated tablet, etc.)
• Clopidogrel (300mg and 75 mg oral tablet)
14. CMS164v2: Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
14
+ Diagnoses must include a start date and have no end date or have an
end date that has not passed to qualify the patient for the denominator.
The Dx start date does not need to be during the measurement year.
+ Prescriptions and medications added to the patient’s medication list that
are “active” will qualify the patient for the numerator.
A start date must be recorded for these medications to be included in
CQM calculations (but the start date does not need to be during the
measurement year).
Active medications and prescriptions are those without a stop date or
those with a stop date that has not already passed.
15. CMS182v3: Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
NQS Domain Clinical Processes/Effectiveness
Denominator Numerator
Patients 18 years of age and older with a visit
during the measurement period, and an active
diagnosis of ischemic vascular disease (IVD)
during the measurement period.
Numerator 1: Patients with a complete lipid profile
performed during the measurement period
Numerator 2: Patients whose most recent LDL-C level
performed during the measurement period is <100 mg/dL
Practice
Fusion
Suggested
Workflow
This measure requires recorded lab results in the EHR. The following lab results meet
the criteria for Numerator 1 of this CQM:
• Lipid panel with direct LDL - Serum or Plasma (LOINC 57698-3), OR
• Lipid 1996 panel - Serum or Plasma (LOINC 24331-1), OR
• ALL of the following together during the measurement period:
• Total cholesterol Laboratory test (LOINC 2093-3)
• HDL-C Laboratory test (LOINC 2085-9)
• LDL-C Laboratory Test (LOINC 13457-7, 18262-6, or 2089-1)
• Triglycerides Laboratory test (LOINC 12951-0 or 2571-8)
17. CMS127v2: Pneumonia Vaccination Status for Older Adults
NQS Domain Clinical Processes/Effectiveness
Denominator Numerator
Patients 65 years of age and
older with a visit during the
measurement period.
Patients who have ever received a pneumococcal
vaccination.
Practice Fusion
Suggested
Workflow
Vaccines (both administered and historical) are entered in the Practice
Fusion in the immunizations screen.
• The pneumococcal vaccine can be recorded in the patient chart
under the Immunizations section of the EHR as “administered” or
“historical.”
• Data of vaccine must be before or during the measurement
period to count in the numerator.
• The only pneumococcal vaccine that meets this measure is
Pneumococcal polysaccharide vaccine, 23 valent (CVX 33)
18. CMS127v2: Pneumonia Vaccination Status for Older Adults
18
+ Access the patient’s immunizations section
+ Select whether the immunization was “Administered” or
“Historical”
+ Search for Pneumococcal, select “Pneumococcal, 23-valent,
adult”, include an administered date, and save
19. CMS125v2: Breast Cancer Screening
NQS Domain Clinical Processes/Effectiveness
Denominator Numerator
Women 41–69 years of age with a
visit during the measurement period.
Women with one or more mammograms during the measurement
period or the year prior to the measurement period.
Practice Fusion
Suggested
Workflow
• Breast cancer screenings must be recorded as “Performed” in the
Screenings/Intervention/Assessments section of the new chart note.
• Screenings that are dated during the measurement year or in the year prior
to the measurement year will count towards this measure.
• Screening assessments that meet the numerator of this measure include:
• Screening mammography
• Diagnostic mammography
• Breast mammogram screening
• Right mammogram screening
• Bilateral mammogram screening
• Breast mammogram spot
• Breast mammogram grid
20. CMS125v2: Breast Cancer Screening
20
Search for “Breast mammography screening” and select “Performed.” A result is not
required for this measure and the date of the screening is defaulted to the date of the chart
note unless otherwise changed by the provider.
Additional Tips
+ Women who had a bilateral
mastectomy or for whom there is
evidence of two unilateral
mastectomies recorded in the
EHR are excluded from this
measure.
+ Providers can record breast
cancer screenings that were
performed by another provider for
the purposes of this measure
using the same method of
recording under the
Screenings/Intervention/Assessm
ents section of the chart note.
21. CMS144v2
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
NQS Domain Clinical Processes/Effectiveness
Denominator Numerator
All patients aged 18 years and older with at least two encounters during the
measurement period, AND:
1) A Dx of heart failure, AND
2) One of the following:
• LVEF result that is <40%, OR
• A Dx of moderate or severe LVSD,
That occurs before or during the second encounter for the patient during the
measurement year.
Patients who were prescribed beta-blocker
therapy within a 12 month
period when seen in the outpatient
setting.
Practice
Fusion
Suggested
Workflow
• Patient is added to the measure denominator after their 2nd encounter of the measurement period.
• Beta-blockers that meet the numerator criteria for this measure include (but are not limited to):
• 24 HR Hydrochlorothiazide 12.5 MG / Metoprolol Tartrate 50 MG Extended Release Tablet
• 24 HR Metoprolol Tartrate 50 MG Extended Release Tablet (other dosages qualify as well)
• 24 HR carvedilol phosphate 80 MG Extended Release Capsule (other dosages qualify as well)
• Bisoprolol Fumarate 5 MG / Hydrochlorothiazide 6.25 MG Oral Tablet (other dosages qualify as
well)
• Carvedilol 25 MG Oral Tablet (other dosages qualify as well)
22. CMS144v2
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
22
+ Providers should ensure patients are prescribed or have an active medication for beta-blockers at any
encounter in which the patient meets the denominator criteria for this measure:
A Dx of heart failure, AND
One of the following:
1) LVEF result that is <40%, OR
2) A Dx of moderate or severe LVSD
+ LVEF results must be received as structured lab results in Practice Fusion
+ This CQM does not have any denominator exclusions, but the following represent denominator
exceptions:
Documentation of medical reason(s) for not prescribing beta-blocker therapy (eg, low blood pressure, fluid overload,
asthma, patients recently treated with an intravenous positive inotropic agent, allergy, intolerance, other medical
reasons)
Documentation of patient reason(s) for not prescribing beta-blocker therapy (eg, patient declined, other patient
reasons)
Documentation of system reason(s) for not prescribing beta-blocker therapy (eg, other reasons attributable to the
healthcare system)
23. CMS147v2: Preventative Care and Screening: Influenza Immunization
NQS Domain Population/Public Health
Denominator Numerator
All patients aged 6 months and older with at least two encounters
during the measurement period and one encounter that occurred
between October 1st of the previous measurement period and
March 31st of the current measurement period.
Patients who received an influenza
immunization OR who reported
previous receipt of an influenza
immunization
Practice
Fusion
Suggested
Workflow
• This measure is looking to see whether patients received the influenza vaccine during a
single flu season that occurs between October 1st of the previous year and March 31st of
the current year.
• Influenza vaccines that meet this measure include:
• Influenza, seasonal injectable (CVX 141)
• Influenza seasonal, injectable, preservative free (CVX 140)
• Influenza, high dose seasonal, preservative-free (CVX 135)
• Influenza, live, intranasal, quadrivalent (CVX 149)
• Seasonal influenza, intradermal, preservative free (CVX 144)
• Influenza, injectable, quadrivalent, preservative free (CVX 150)
• Influenza virus vaccine, live, attenuated, for intranasal use (CVX 111)
24. CMS147v2: Preventative Care and Screening: Influenza Immunization
24
+ Previous receipt of influenza (such as a patient who received the vaccine at work) can
be recorded:
In the Screenings/Intervention/Assessments section of the chart note by search for
“Has influenza vaccination at…” or
By recording a “historical” vaccine in the immunization section of the EHR and
including a date between October 1st - March 31st
+ To enable reporting of this measure at the close of the reporting period, this measure
will only assess the influenza season that ends in March of the reporting period. The
subsequent influenza season (ending March of the following year) will be measured and
reported in the following year.
25. CMS139v2: Falls: Screening for Future Fall Risk
NQS Domain Patient Safety
Denominator Numerator
Patients aged 65 years and older with
a visit during the measurement period.
Patients who were screened for future fall risk at
least once within the measurement period.
Practice
Fusion
Suggested
Workflow
• Future fall risk: Patients are considered at risk for future falls if they have
had 2 or more falls in the past year or any fall with injury in the past year.
• Search for “Falls Risk Assessment” in the
Screenings/Interventions/Assessments section of the chart note and
indicate that it has been “performed.”
• The start date defaults to the date of the chart note but can be
backdated if needed.
• A result is not needed for the Falls Risk Assessment.
26. CMS139v2: Falls: Screening for Future Fall Risk
26
+ Search and record “Falls Risk Assessment” as “Performed” in the
Screenings/Interventions/Assessments section of the new chart note.
+ A result is not needed and the start date is defaulted to the date of the encounter. An
end date is not needed for this CQM.
27. CMS155v2:
Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents
NQS Domain Population/Public Health
Denominator Numerator
Patients 3-17 years of age with at
least one outpatient visit with a
primary care physician (PCP) or an
obstetrician/gynecologist (OB/GYN)
during the measurement period.
Numerator 1: Patients who had a height, weight and body mass
index (BMI) percentile recorded during the measurement period
Numerator 2: Patients who had counseling for nutrition during the
measurement period
Numerator 3: Patients who had counseling for physical activity
during the measurement period
Practice
Fusion
Suggested
Workflow
• BMI percentile is automatically calculated for patients in this age range who have height
and weight recorded
• Counseling for nutrition and physical activity are recorded under the
Screenings/Intervention/Assessments section
• Examples of interventions for counseling for nutrition (numerator 2) include: “nutrition education,”
“lifestyle education regarding diet,” and “weight control education.”
• Examples of interventions for counseling for physical activity (numerator 3) include: “exercise
education,” “patient advised about exercise,” and “recommendation to exercise.”
28. CMS155v2:
Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents
28
+ To meet Numerator 1, providers
must record the height and weight
during the measurement period.
+ Numerator 2 includes all of the
requirements of Numerator 1 +
recording an intervention of
counseling for nutrition.
+ Numerator 3 includes all of the
requirements of Numerator 1 +
Numerator 2 + recording an
intervention for counseling for
physical activity.
29. CMS126v2: Use of Appropriate Medications for Asthma
NQS Domain Clinical Processes/Effectiveness
Denominator Numerator
Patients 5-64 years of age with
persistent asthma and a visit during
the measurement period.
Patients who were dispensed at least one prescription
for a preferred asthma therapy during the
measurement period.
Practice Fusion
Suggested
Workflow
“Persistent Asthma” for the purposes of this CQM must be recorded
using SNOMED by searching for and adding one of the following
diagnoses with a start date on or before the encounter:
• Moderate persistent asthma
• Mild persistent asthma
• Severe persistent asthma
Patients whose charts only include the ICD-9 code 493.90 (Asthma)
will not be included in this measure denominator.
30. CMS126v2: Use of Appropriate Medications for Asthma
30
+ For the moment, providers will not be able to record that a
medication has been dispensed for the purposes of this
CQM.
+ This is a required CQM for Comprehensive Primary Care
Initiative – other providers should not select this CQM for
reporting unless absolutely necessary.
31. CMS163v2: Diabetes: Low Density Lipoprotein (LDL) Management
NQS Domain Clinical Processes/Effectiveness
Denominator Numerator
Patients 18-75 years of age with diabetes
with a visit during the measurement
period.
Patients whose most recent LDL-C level
performed during the measurement period is
<100 mg/dL.
Practice
Fusion
Suggested
Workflow
The LDL-C test results that meet the numerator criteria for this measure
include:
• Cholesterol in LDL [Mass/volume] in Serum or Plasma (LOINC 2089-1)
• Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay
(LOINC 18262-6)
• Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation
(LOINC 13457-7)
32. CMS163v2: Diabetes: Low Density Lipoprotein (LDL) Management
32
+ This measure will look for the most recent (e.g. the last recorded) LDL-C result
in the EHR that occurred during the measurement period for the purposes of
the numerator criteria.
+ Patients with a diagnosis of gestational diabetes are excluded from this
measure.
33. CMS124v2: Cervical Cancer Screening
NQS Domain Clinical Processes/Effectiveness
Denominator Numerator
Women 23-64 years of age with a visit
during the measurement period.
Women with one or more Pap tests during the measurement
period or the two years prior to the measurement period.
Practice
Fusion
Suggested
Workflow
Pap test results can be sent to the Practice Fusion EHR by a lab partner.
The lab test results that meet the numerator criteria for this measure include (but are not
limited to):
• Cytology report of Cervical or vaginal smear or scraping Cyto stain (LOINC 47528-5)
• Cytology report of Cervical or vaginal smear or scraping Cyto stain thin prep (47527-7)
• Cytology Cervical or vaginal smear or scraping study (33717-0)
• Cytology study comment Cervical or vaginal smear or scraping Cyto stain (19774-9)
• Microscopic observation [Identifier] in Cervix by Cyto stain thin prep (18500-9)
• Microscopic observation [Identifier] in Cervix by Cyto stain (10524-7)
34. CMS124v2: Cervical Cancer Screening
34
+ Cervical cancer screenings cannot be entered into the EHR under
Screenings/Intervention/Assessments
+ They must be sent to the EHR by a lab partner
35. CMS153v2: Chlamydia Screening for Women
NQS Domain Population/Public Health
Denominator Numerator
Women 16 to 24 years of age who are sexually active and
who had a visit in the measurement period.
Women with at least one chlamydia test
during the measurement period.
Practice
Fusion
Suggested
Workflow
Codes to identify sexually active women include codes for:
• pregnancy
• sexually transmitted infections
• contraceptives
• contraceptive devices
• infertility treatments
36. CMS153v2: Chlamydia Screening for Women
36
+ The U.S. Preventive Service Task Force recommends that sexually active non-pregnant
young women age 24 years or younger and older women (pregnant or
not) who are at increased risk should be screened for a chlamydial infection.
+ Chlamydia test results must come through structured lab results into the EHR.
+ Women who receive a pregnancy
test solely as a safety precaution
before ordering an x-ray or
specified medications are
excluded from this measure.
Ensure that the pregnancy test and the
associated X-ray are recorded in the EHR
if a patient should be excluded.
X-ray data elements can be found in the
Screenings/Intervention/Assessment
section of the chart note.
37. CMS149v2: Dementia: Cognitive Assessment
NQS Domain Clinical Processes/Effectiveness
Denominator Numerator
All patients, regardless of age, with a
diagnosis of dementia and at least two
encounters during the measurement period.
Patients for whom an assessment of cognition is
performed and the results reviewed at least once within a
12 month period.
Practice
Fusion
Suggested
Workflow
Cognitive assessments are conducted outside of the EHR but can be recorded in the
patient chart under Screenings/Intervention/Assessments. Standardized assessments that
meet this CQM criteria include:
• Total score BOMC
• Total score MoCA
• Total score MMSE
• Total score AD8
• Total score IQCODE
• Total score SLUMS
• Prior assessment brief interview for mental status (BIMS) summary score MDSv3
38. CMS149v2: Dementia: Cognitive Assessment
38
+ Patients will be added to the denominator of this measure in the CQM report after their
2nd encounter.
+ The cognitive assessment should be conducted and recorded during the 1st encounter
during the measurement period and reviewed during the 2nd encounter of the
measurement period
However, this CQM will give credit if the assessment is recorded during any
encounter during the measurement year (since review of the assessment is not
measured as part of this CQM).
+ Use of a standardized tool or instrument to assess cognition other than those listed in
the previous table will still meet numerator performance.
Search and record the data element “Assessment and interpretation of higher
cerebral function, cognitive testing” if you use an assessment tool not otherwise
listed.
39. Resources
+ Practice Fusion Quality Programs Page
http://www.practicefusion.com/physician-quality-programs/
+ CMS Eligibility Site
http://cms.gov/eHealth/downloads/EligibilityChart_090513_FINAL.p
df
+ PQRS Resources on Practice Fusion
http://www.practicefusion.com/blog/resources-and-faqs-on-cqms-and-
pqrs-2014/
+ CQMs on the Forum
https://forum.practicefusion.com/practicefusion/topics/how_does_th
e_2014_cqm_report_work?
39
40. Assistance
+ QualityNet Help Desk
+ CMS’s resource on the PQRS program
+ Available Monday – Friday; 7:00 AM-7:00 PM CST
+ Phone: 1-866-288-8912
+ Email: Qnetsupport@hcqis.org
Editor's Notes
There are a lot of terms used when discussing and understanding quality measures. The definitions below will help you better use this guide to measure and monitor the quality of care that you provide to your patients.
Denominator – The population of patients or encounters for which the measure applies.
Numerator - The population of patients from the denominator who meet the measure specified clinical requirements or the population of encounters from the denominator where the measure specific requirement has been performed.
Exclusion/Exception – Specifications that would remove a patient from the denominator of a specific quality measure. These exclusions and exceptions include certain diagnoses that make it clinically unnecessary for the patient to receive the numerator clinical action and/or provider or patient determined reasons for refusing certain clinical actions.
Measurement period – This is also known as the EHR reporting period and refers to the time frame for which the CQMs will be calculated. For more information on determining your CQM reporting period, refer to the reporting requirements at the end of this guide.
National Quality Strategy (NQS) Domains – The National Quality Strategy outlines the federal plan to improve the quality of healthcare delivered in the United States and was developed as a result of the Affordable Care Act. The six NQS domains, one of which is assigned to each CMS eCQM, are: Patient and Family Engagement, Patient Safety, Care Coordination, Population and Public Health, Efficient Use of Healthcare Resources, and Clinical Processes/Effectiveness. Information on what NQS domain applies to which measure is available in the Practice Fusion CQM report and in the Practice Fusion CQM Calculation Guide.
National Quality Forum (NQF) – The National Quality Forum reviews, endorses, and recommends use of standardized quality measures. Not all quality measures are “NQF-endorsed,” but those that are have an assigned NQF number.
Value sets - Lists of specific values (terms and their codes) derived from single or multiple standard vocabularies used to define clinical concepts (e.g. patients with diabetes, clinical visit, reportable diseases) used in clinical quality measures and to support effective health information exchange. Although there are many uses for value sets, a primary purpose of the value sets is to support the 2014 Clinical Quality Measures prescribed for Meaningful Use. Most of the value sets are therefore used to define the patient populations that should be included in the denominators and in the numerators when computing a clinical quality measure.
Quality Reporting Document Architecture (QRDA) – An HL7-based standard document format for the exchange of clinical quality measure data. QRDA reports contain data extracted from electronic health records (EHRs) and other information technology systems. QRDA reports are used for the exchange of CQM data between systems for a variety of quality measurement and reporting initiatives, including Meaningful Use and PQRS. These programs require the submission of QRDA Category I reports, which utilize patient-level data, or QRDA Category III reports, which utilize aggregated patient data.
Bug right now for recording
LVEF result would need to be recorded via manual lab result entry.